Michael J.  LaBarre net worth and biography

Michael LaBarre Biography and Net Worth

Dr. LaBarre brings to Halozyme more than 25 years of experience across all aspects of biopharmaceutical research and drug development, including strong expertise in chemistry, manufacturing, and controls (CMC), regulatory strategy and product development. Dr. LaBarre joined Halozyme in 2008 and has held leadership positions in product development, alliance management, research, and regulatory affairs during that time. He is currently responsible for providing scientific and technical leadership across all Halozyme programs and is the lead expert on Halozyme’s ENHANZE® drug delivery technology.

Prior to Halozyme, Dr. LaBarre served as Vice President of Product Development at Paramount BioSciences, LLC, where he led CMC and research efforts for the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served from 1995 to 2006 in various research and development positions at Biogen Idec (formerly IDEC before the merger with Biogen in 2004), where he supported numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. and he began his career at Hybritech in San Diego in 1992. Dr. LaBarre also taught chemistry laboratory for several years as an adjunct professor at Mesa Community College early in his career.

Dr. LaBarre received his B.S. in Chemistry from Southampton College of Long Island University and his Ph.D. in Chemistry from the University of Arizona.

What is Michael J. LaBarre's net worth?

The estimated net worth of Michael J. LaBarre is at least $6.04 million as of March 12th, 2024. Mr. LaBarre owns 156,558 shares of Halozyme Therapeutics stock worth more than $6,044,704 as of April 16th. This net worth evaluation does not reflect any other assets that Mr. LaBarre may own. Additionally, Mr. LaBarre receives an annual salary of $843,890.00 as SVP at Halozyme Therapeutics. Learn More about Michael J. LaBarre's net worth.

How old is Michael J. LaBarre?

Mr. LaBarre is currently 60 years old. There are 3 older executives and no younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics is Dr. Christopher Bryant Ph.D., Chief Manufacturing Officer & Head of Technical Operations, who is 63 years old. Learn More on Michael J. LaBarre's age.

What is Michael J. LaBarre's salary?

As the SVP of Halozyme Therapeutics, Inc., Mr. LaBarre earns $843,890.00 per year. There are 2 executives that earn more than Mr. LaBarre. The highest earning executive at Halozyme Therapeutics is Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., President, CEO & Director, who commands a salary of $1,820,000.00 per year. Learn More on Michael J. LaBarre's salary.

How do I contact Michael J. LaBarre?

The corporate mailing address for Mr. LaBarre and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Michael J. LaBarre's contact information.

Has Michael J. LaBarre been buying or selling shares of Halozyme Therapeutics?

Michael J. LaBarre has not been actively trading shares of Halozyme Therapeutics in the last ninety days. Most recently, Michael J. Labarre sold 10,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a transaction totalling $416,400.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares of the company's stock, valued at $6,519,075.12. Learn More on Michael J. LaBarre's trading history.

Who are Halozyme Therapeutics' active insiders?

Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.

Are insiders buying or selling shares of Halozyme Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 160,000 shares worth more than $6,522,300.00. The most recent insider tranaction occured on March, 12th when SVP Michael J Labarre sold 10,000 shares worth more than $416,400.00. Insiders at Halozyme Therapeutics own 2.7% of the company. Learn More about insider trades at Halozyme Therapeutics.

Information on this page was last updated on 3/12/2024.

Michael J. LaBarre Insider Trading History at Halozyme Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2024Sell10,000$41.64$416,400.00156,558View SEC Filing Icon  
2/28/2024Sell10,000$39.55$395,500.00156,558View SEC Filing Icon  
12/12/2023Sell10,000$39.63$396,300.00151,911View SEC Filing Icon  
10/17/2023Sell10,000$36.52$365,200.00151,911View SEC Filing Icon  
9/19/2023Sell10,000$39.10$391,000.00151,911View SEC Filing Icon  
8/22/2023Sell10,000$42.41$424,100.00151,911View SEC Filing Icon  
8/22/2023Sell10,000$42.41$424,100.00151,911View SEC Filing Icon  
7/18/2023Sell10,000$40.43$404,300.00141,911View SEC Filing Icon  
6/21/2023Sell10,000$36.00$360,000.00141,911View SEC Filing Icon  
4/18/2023Sell10,000$36.00$360,000.00141,911View SEC Filing Icon  
2/27/2023Sell10,000$49.55$495,500.00138,927View SEC Filing Icon  
2/15/2023Sell10,000$48.39$483,900.00143,477View SEC Filing Icon  
1/17/2023Sell10,000$50.46$504,600.00143,137View SEC Filing Icon  
12/13/2022Sell10,000$58.67$586,700.00153,137View SEC Filing Icon  
11/15/2022Sell10,000$54.13$541,300.00163,137View SEC Filing Icon  
10/1/2021Sell29,450$39.93$1,175,938.50View SEC Filing Icon  
7/1/2021Sell40,315$45.70$1,842,395.50View SEC Filing Icon  
4/1/2021Sell28,689$42.56$1,221,003.84
3/1/2021Sell18,324$45.81$839,422.44129,330View SEC Filing Icon  
12/21/2020Sell12,000$42.58$510,960.00123,400View SEC Filing Icon  
11/20/2020Sell12,000$38.76$465,120.00142,689View SEC Filing Icon  
10/20/2020Sell12,000$30.43$365,160.00146,800View SEC Filing Icon  
9/21/2020Sell12,000$26.91$322,920.00158,800View SEC Filing Icon  
8/20/2020Sell12,000$28.30$339,600.00170,800View SEC Filing Icon  
7/20/2020Sell12,000$29.01$348,120.00182,800View SEC Filing Icon  
5/20/2020Sell21,387$23.80$509,010.60197,574View SEC Filing Icon  
See Full Table

Michael J. LaBarre Buying and Selling Activity at Halozyme Therapeutics

This chart shows Michael J Labarre's buying and selling at Halozyme Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Halozyme Therapeutics Company Overview

Halozyme Therapeutics logo
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $38.38
Low: $38.10
High: $38.81

50 Day Range

MA: $39.39
Low: $34.64
High: $41.95

2 Week Range

Now: $38.38
Low: $29.85
High: $45.00

Volume

642,294 shs

Average Volume

1,285,641 shs

Market Capitalization

$4.88 billion

P/E Ratio

18.19

Dividend Yield

N/A

Beta

1.25